Pancytopenia
10
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
Spectrum of Hematological Disorders in Pediatrics
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
Collection of Blood From Patients With Pancytopenia
Management of Childhood Pancytopenia
Gene Therapy for the Treatment of Fanconi's Anemia Type C
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders
Stem Cell Factor Medication for Aplastic Anemia